Comprehensive cell line screening assays integrated with downstream pharmacological services Cell panel  of 600+ human cancer cell lines for single agent or combinatory drug screening, covering 30+ cancer types 100+ mouse cell lines, across 20+ cancer types 95 PDX-derived cell lines 320+ CDX models, ready for use 1,400+ PDX models, for primary tumor cell line …Read More >

Multidisciplinary testing platforms that enable support to detect, develop, and validate biomarkers of cancer. End-to-end services in pathology, flow cytometry, and molecular biology techniques Rigorous quality management system, and well-established sample and data management procedures System biology analysis utilizing multidisciplinary testing platforms CAP-accredited clinical biomarker lab has been established since 2015 View our comprehensive platform …Read More >

Oncology & Immunology Services From the generation and characterization of genetically engineered animal models (GEAMs) to colony management and pre-clinical pharmacology research GEAM generation and characterization Full suite of in vitro testing assays Efficacy, toxicity, and PK/PD services Behavioral assessment platform Large in-house collection of GEAMs (KO/KI, mouse & rat) across multiple therapeutic areas, including: …Read More >

Macrocyclic peptides are an emerging molecular class for targeting intracellular protein–protein interactions (PPIs) and for providing an oral modality for drug targets. Herein, we use DNA-encoded cyclic peptide libraries to discover a neutral nonapeptide, UNP-6457, that inhibits MDM2–p53 interaction with an IC50 of 8.9 nM. These studies showcase how tailored DEL libraries can directly yield …Read More >

Our comprehensive panel of orthotopic and metastasis syngeneic models includes: 17 orthotopic/disseminated models covering 10 cancer types; Organ-based orthotopic models of solid tumor cell lines; IV injection disseminated models of hematopoietic cancer cell lines; 13 experimental metastasis models covering 7 cancer types

DLL3 related lung cancer PDX models, validated by RNA-Seq and IHC staining

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification or gene mutation can promote the development of multiple cancer types, including gastric, liver, lung, breast, pancreatic cancer, and glioblastoma (through the stimulation of multiple signaling pathways).  As a result, c-Met is considered a clinically …Read More >

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of …Read More >